5th Annual IBDHorizons Midwest Symposium

New this year: Research Plenary session with oral presentations and a Scientific Abstract Poster forum

Course Information

  • 1 Day – Novel multiplatform in-person & virtual attendance covering the Pacific Northwest region with an estimated 200 attendees.
  • In-person attendance will be limited to meet the highest safety standards. A complete virtual conference platform will be offered exclusively if in-person attendance cannot be safely conducted.
  • Format will include a series of IBD-focused presentations, panel discussions, and case studies with dynamic attendee participation using audience interactive technology.

Intended Audience

This activity was developed for gastroenterologists, advanced nurse practitioners, physician assistants, gastroenterology nurses, pharmacists, and surgeons involved in the care of patients with IBD.

Learning Objectives

After completion of this activity, participants will be able to:

  1. Analyze the currently available tools to stratify the risk of patients developing complicated IBD vs. mild IBD at diagnosis and the subsequent implications on treatment goals and strategies.
  2. Describe the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these agents in IBD today.
  3. Outline the goals of IBD care and incorporate the latest concepts, including treat-to-target in IBD clinical practice to optimize patient outcomes.  
  4. Identify the current endoscopic assessment tools and scoring systems and their practical application in IBD management. 
  5. Assess the latest evidence regarding the role of therapeutic drug monitoring, proactive and reactive, to optimize response to biologic therapy in patients with IBD.
  6. Recognize the various medical and surgical challenges for patients who receive an ileoanal pouch and the latest management recommendations.
  7. Review our current understanding of the microbiome in IBD and microbiome manipulation in the management of IBD today.
  8. Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.

  • Accreditation:

    Accreditation statements to be announced..

Date

Feb 12 2022

Time

8:00 am - 3:30 pm

Location

Hilton Columbus Downtown
01 N High St, Columbus, OH 43215

Speakers

  • Anita Afzali
    Anita Afzali
    MD, MPH, Associate Professor of Clinical Medicine, Gastroenterologist, Medical Director of OSU IBD Center, Director of Operations for the Division of Gastroenterology, Hepatology and Nutrition

    Dr. Anita Afzali is an Associate Professor of Clinical Medicine and a Gastroenterologist that specializes in Inflammatory Bowel Disease (IBD) at The Ohio State University Wexner Medical Center. She is the Director of Operations for the Division of Gastroenterology, Hepatology, and Nutrition, as well as the Medical Director of the OSU Inflammatory Bowel Disease Center. She holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. Her research interests include clinical outcomes and association of bowel and joint disease, the influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity Committee.

  • Brian Feagan
    Brian Feagan
    MD

    Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).

    Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).

  • Edward Loftus Jr.
    Edward Loftus Jr.
    MD, Professor of Medicine

    Dr. Edward V. Loftus is a gastroenterologist in Rochester, Minnesota, and is affiliated with Mayo Clinic. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice for more than 20 years.
    Dr. Loftus specializes in gastroenterology and IBD. He has been the recipient of numerous awards and honors over his years in practice, including but not limited to America’s Top Doctors and Teacher of the Year in 2010.

  • Feza Remzi
    Feza Remzi
    MD, Colorectal Surgeon at NYU Langone, Director of IBD Center, Professor of Surgery and NYU School of Medicine

    As a colorectal surgeon at NYU Langone, Dr. Remzi is a foremost expert in the surgical management of Inflammatory Bowel Disease, also known as Crohn’s Disease and Ulcerative Colitis. Dr. Remzi performs pelvic pouch surgery and complex abdominopelvic re-operative surgery, as well as sphincter-saving surgery for rectal cancer, applying minimally invasive techniques to manage colorectal conditions. Dr. Remzi serves as the director of the Inflammatory Bowel Disease Center and is one of the few colorectal surgeons in the world who is specialized in caring for people who are experiencing problems with a prior pelvic pouch, or J-pouch, procedures. He states “I have been humbled and privileged to be able to help my patients for more than 20 years. I treat my patients the way I would treat my own family. I take a team approach to care, so we bring together medical, surgical, and nursing professionals who devote 100 percent of their efforts to giving patients a better chance at life. Many of the people I treat are experiencing complex problems that impact not only their own quality of life but also that of their families. Therefore, I include patients’ family members as a part of the treatment team.” As a national and international expert in colorectal surgery, Dr. Remzi has published many articles and book chapters on the surgical management of Inflammatory Bowel Disease, ileal J-pouch surgery, and re-operative abdominopelvic surgery. He is an honored member of the American Surgical Association and is humbled to be one of only a handful of surgeons in the world who is a member of the International Organization For the Study of Inflammatory Bowel Disease.

  • Ghassan Wahbeh
    Ghassan Wahbeh
    MD, Director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital

    Ghassan Wahbeh, MD, is the director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with Crohn’s Disease and Ulcerative Colitis, including advanced therapeutics and pre and post-surgery IBD management. Dr. Wahbeh’s research interests include advanced management of moderate and severe colitis in the outpatient and inpatient setting, managing complicated Crohn’s disease including fistulizing and stricturing phenotypes, mucosal healing in IBD, navigating surgical options in IBD and novel therapies.
 Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training, and fellow physician specialty training. He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohns & Colitis Foundation service award. He continues to serve as a member of the National Professional Education Committee and the Northwest Medical Advisory Committee of the Crohns and Colitis Foundation of America.

  • Jessica Allegretti
    Jessica Allegretti
    MD, MPH, Associate Director, Crohn's and Colitis Center Assistant Professor, Harvard Medical School

    Dr. Jessica Allegretti is an attending gastroenterologist at the BWH Crohn’s and Colitis Center, where she also serves as the center’s Director of Clinical Trials. Dr. Allegretti is extremely dedicated to providing high quality patient care while also conducting important clinical research that will advance the field and provide important opportunities for her patients.

    In addition to her clinical responsibilities and caring for patients with IBD, Dr. Allegretti is the director of the fecal transplant program for recurrent clostridium difficile at Brigham and Women’s Hospital. She has also participated in multiple clinical trials investigating the use of fecal transplants in other diseases such as inflammatory bowel disease. She is also leading several research projects assessing the treatment of inpatients with ulcerative colitis, and rational de-escalation of infliximab doses in patient with Crohn’s disease.

    Dr. Allegretti received a grant from the American College of Gastroenterology to further investigate the mechanisms of recurrent clostridium difficile infections and is the lead author of multiple research articles, review papers, and book chapters that have been published in prestigious peer-reviewed journals.

    She is also an Instructor of Medicine at Harvard Medical School. As an instructor at the medical school, Dr. Allegretti teaches and trains medical students, residents, and research fellows.

    Dr. Allegretti graduated from Cornell University in Ithaca New York, and The Miller School of Medicine at the University of Miami in Miami, Florida. She was trained in internal medicine at Massachusetts’s General Hospital and completed her gastroenterology fellowship training at Brigham and Women’s Hospital. She later went on to receive a Master’s in Public Health from the Harvard School of Public Health.

  • Marla Dubinsky
    Marla Dubinsky
    Chief of the Division of Pediatric Gastroenterology

    Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Kravis Children’s Hospital at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in 120 peer reviewed journals including Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.

  • Scott D. Lee
    Scott D. Lee
    MD, Associate Professor of Medicine

    Dr. Scott D. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology, and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.

QR Code
  • Accreditation:

    Accreditation statements to be announced..

QR Code

Leave a Reply

Your email address will not be published. Required fields are marked *